←
Majzner_Lab387 posts
Majzner_Lab avatar

Majzner_Lab

@Majzner_Lab

Robbie Majzner's Lab at Dana Farber. Focus on CAR T cell signaling & engineering, cancer immunotherapy & ganglioside biology. Interested in curing kids!

◷ Joined April 2021▧ 20 Photos and videos
Kids V Cancer avatar
⟳ Majzner_Lab retweeted
Kids V Cancer@KIDSvCANCER·Oct 24

Let’s make the PRV permanent! The PRV program provides an incentive, a voucher, to companies that develop new drugs for kids with life threatening illnesses. It has been a wildly successful program. The PRV program has resulted in over 75 new drugs for kids since it was first passed into law in 2012. Over $10 billion incentives have been created at no cost to taxpayers. Vouchers now trade for over $200 million. bilirakis.house.gov/media/pr… Making the PRV program permanent is important because biotechs need to know the incentive will not expire, as it did from 2023 to early this year.

Surbhi Sidana, MD avatar
⟳ Majzner_Lab retweeted
Surbhi Sidana, MD@SurbhiSidanaMD·Jun 14

Level of BCMA expression matters for BCMA CAR-T! #mmsm nature.com/articles/s41408-0… @MasoomaRana_ - BCMA universally +, but heterogeneous - Flow better vs IHC -Higher BCMA expression -⬆️ PFS with cilta-cel & ide-cel -Relapse: Downregulation common, loss rare #mmsm #cartsm

Majzner_Lab avatar
Majzner_Lab@Majzner_Lab·May 6

Thank you @psscra @PershingSqFdn @BillAckman @SohnConf for the support of our work to engineer more effective immunotherapies for children and adults with cancer!

We are thrilled to announce the 13 winners of the 2026 Pershing Square Sohn Cancer Prize. Doubling our commitment, this year's scientists have been selected for their bold ideas and potential to transform cancer research. Please join us in congratulating: pershingsquarephilanthropies…

Majzner_Lab avatar
Majzner_Lab@Majzner_Lab·18 Dec 2025

Congrats to Kevin Lu from the lab on receiving this great award from @chadtough and the Violet Foundation for Pediatric Cancer! We really appreciate the support and the dedication to help children with DIPG!

Fellowship Grant awarded to Kevin Lu of Dana-Farber Cancer Institute, mentored by Robbie Majzner and Mariella Filbin. (co-funded by the Violet Foundation for Pediatric Brain Cancer) @Majzner_Lab @FilbinMariella

Post attachment
Majzner_Lab avatar
Majzner_Lab@Majzner_Lab·15 Dec 2025

Really excited for the news today as Link Cell Therapies officially launches out of stealth with the announcement of their Series A. The company has been hard at work for several years turning a prototype Boolean-logic AND-gated CAR T cell into a real product with real potential to help patients. With LNK001 headed towards a Phase 1 trial in renal cell carcinoma in 2026, we are excited about the team Link has built - and we hope their work will redefine the universe of antigens and cancers we can target with CAR T cells. Very fortunate to have received backing from @samsaracapital, @JNJInnovation, @bmsnews, @KyowaKirin_US, @Wing_VC, Sheatree Capital, Sherpa Healthcare Partners, & others. fiercebiotech.com/biotech/li…

Majzner_Lab avatar
Majzner_Lab@Majzner_Lab·15 Dec 2025

Thanks Ansu for the vote of confidence first in the lab and now with the funding! Really happy to have Wing's backing!

Excited to support Link Cell Therapies' $60M Series A as they emerge from stealth and to partner with an outstanding syndicate led by @JNJInnovation, with participation from @samsaracapital, Sheatree Capital, @bmsnews Bristol Myers Squibb, @KyowaKirin_US, Sherpa Healthcare Partners, and other strategic investors. I first encountered Link’s groundbreaking technology when it was just a twinkle in founder @Majzner_Lab's eye at Stanford—and @Wing_VC is thrilled to support Link's pioneering work as they take this discovery to the clinic. High-fidelity AND-gated CAR-T therapies will unlock ex vivo and in vivo CAR-T efficacy for solid tumors, and the company's first lead program LNK001 aims to deliver a precise, dual-antigen approach that tackles the persistent on-target/off-tumor toxicity challenge in renal cell carcinoma (RCC). Congratulations to Robbie and co-founder Crystal Mackall, and to the entire Link Cell Therapies team! Looking forward to watching this transformative technology progress and bring hope to patients battling cancer.

Chabad Lubavitch HQ avatar
⟳ Majzner_Lab retweeted
Chabad Lubavitch HQ@Lubavitch·14 Dec 2025

STATEMENT BY CHABAD-LUBAVITCH WORLD HEADQUARTERS We are devastated and heartbroken by the barbaric terror attack against a public Chanukah celebration in Sydney, Australia, on the first night of Chanukah. We grieve for the families whose loved ones were murdered, among them Chabad emissary Rabbi Elie Schlanger, who led the Chanukah celebration with the people of Bondi Beach. Rabbi Schlanger devoted his life to sharing Jewish warmth, faith, and community with others. He was doing exactly what he had been sent to do—bringing light and joy into the public square—when his life was cut down. Rabbi Schlanger leaves his wife, Chayale and their children, including a two-month old baby. We mourn him as family and stand with his loved ones and his community in their immeasurable loss. May his memory be for a blessing. We pray that G-d grant healing and comfort to all who survived this attack—men, women, and children—and strength to the families and community now living with its aftermath. Let us be clear: this was a treacherous act of terror—an attack on community, on goodness, and on light itself. It reflects a climate in which Jew-hatred has been allowed to grow and to turn violent. That reality must be confronted. This moment demands accountability. Jewish life must be safeguarded through concrete, heightened measures to deter and rein in calls for violence against Jews. We call on governments and law-enforcement authorities to take responsibility, to strengthen security around Jewish institutions and public gatherings, particularly during Chanukah, when Jewish life is expressed openly and visibly. The Jewish response to terror has never been retreat. Chanukah teaches us to bring light precisely where darkness seeks to intrude. In our times, the Lubavitcher Rebbe, Rabbi Menachem Mendel Schneerson, of blessed memory, insisted that Chanukah lights be placed openly in public spaces as a statement of dignity, faith, and confidence. In that spirit, Chabad-Lubavitch emissaries around the world will continue to light public menorahs—responsibly, in coordination with security authorities, and without surrendering visibility or pride. Jewish life will not be driven from the public square. We will honor the lives taken by enhancing Jewish practice, pride and visibility. May their light rise from this sorrow, and their memory be a blessing to us all. Rabbi Yehuda Krinsky Chairman

Post attachment
Majzner_Lab avatar
Majzner_Lab@Majzner_Lab·20 Nov 2025

This work complements a lot of great stories in the field about enhancing CAR sensitivity including those mentioned above and many more e.g. science.org/doi/10.1126/scit… & nature.com/articles/s41591-0… & nature.com/articles/s43018-0… & nature.com/articles/s41589-0… & cell.com/cancer-cell/fulltex…

Majzner_Lab avatar
Majzner_Lab@Majzner_Lab·20 Nov 2025

My favorite part of the story is that I told Mari to focus on LAT-the bottleneck of TCR signaling & that SLP-76 wouldn't work...It's a sign of a great trainee when she knows what to ignore from her PI-She has taken this work in many new directions & we're excited for what's next!

Majzner_Lab avatar
Majzner_Lab@Majzner_Lab·20 Nov 2025

we found that MT-SLP-76 narrows the therapeutic window &worsens on-target, off-tumor tox...(no wonder enhanced ROR1 CARs haven't found a therapeutic window in the clinic!). this tells us that as we potency enhance CARs, we will likely see more of this tox- choose targets wisely!

Post attachment